Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

Blood. 2020 May 28;135(22):1994-1997. doi: 10.1182/blood.2019004478.
No abstract available

Publication types

  • Letter

MeSH terms

  • Erdheim-Chester Disease / diagnostic imaging
  • Erdheim-Chester Disease / drug therapy*
  • Erdheim-Chester Disease / genetics
  • Follow-Up Studies
  • Humans
  • Mutation
  • Prednisolone / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / genetics
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Protein Kinase Inhibitors
  • Prednisolone
  • MTOR protein, human
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • TOR Serine-Threonine Kinases